This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Improving Treatment Adherence and Outcomes in PAH Patients Who Are Not Meeting Their Treatment Goals

Improving Treatment Adherence and Outcomes in PAH Patients Who Are Not Meeting Their Treatment Goals

Format

Clinical Review

Time to Complete

1 hour

Released

March 26, 2018

Expires

March 26, 2019
Add to Queue


Maximum Credits

1.00 / ANCC Contact Hour
1.00 / AANP Contact Hour (1.00 pharmacology credit)

Accredited Provider



Provided by Advancing Knowledge in Healthcare (AKH) Inc.

Commercial Supporter

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.

Program Description

Pulmonary arterial hypertension (PAH) is a rare, chronic condition characterized by pulmonary vascular resistance, remodeling and occlusion of the pulmonary arterioles, right ventricular dysfunction, right heart failure, and death, if untreated. Data from the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) has shown that the diagnosis of PAH is often missed or delayed with the average length of time from symptom onset to diagnosis estimated to range from 1 to 3 years. A thorough understanding of the diagnosis, classification and functional status of patients with PAH is essential to selecting the optimum therapy for these patients. The purpose of this activity is to focus on several important aspects of PAH management including a review of the pathophysiology, classification, predictors of disease progression and clinical outcomes of PAH; a discussion of clinical trial data on existing and emerging therapeutics for the management of PAH; and a review of effective strategies to improve therapeutic and clinical outcomes in patients with PAH.

Intended Audience

This activity is intended for nurse practitioners, nurses and other providers involved in the management of patients with pulmonary arterial hypertension (PAH).

Educational Objectives

After completing this activity, participants should be able to:

  • Discuss the diagnosis, classification, functional capacity classification, rationale for the use of echocardiography, right heart catheterization (RHC), vasoreactivity testing, and when to referpatients with suspected pulmonary arterial hypertension (PAH) to a specialist center
  • Review the clinical trial data for existing and emerging therapeutics for the management of pulmonary arterial hypertension (PAH)
  • Identify effective provider-patient communication strategies to improve treatment adherence and outcomes for patients with pulmonary arterial hypertension (PAH)

Conflict Of Interest Disclosure Policy

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.

Faculty

Sandra Lombardi, RN
Pulmonary Hypertension Clinical Nurse Coordinator
University of California, San Diego
La Jolla, CA

Ms. Lombardi has disclosed the following relevant financial relationships:
Consultant: Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals, Inc.
Speakers Bureau: Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals, Inc

Martha Kingman, FNP-C, DNP
Nurse Practitioner, Pulmonary Services, Heart and Lung Center
University of Texas Southwestern Medical Center
Dallas, Texas

Ms. Kingman has disclosed the following relevant financial relationships:
Consultant: Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals, Inc., Gilead, United Therapeutics
Speakers Bureau: Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals, Inc., Gilead, United Therapeutics

Accredited Provider Disclosure

STAFF/REVIEWERS
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP
, Medical Writer/Interviewer, has disclosed no relevant financial relationships.

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.

Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.

Credit

1.00

Type

CE for Nurses

Accreditation Statement

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This activity is awarded 1.0 Contact Hours.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement


AKH, Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803.

Designation Statement

This activity is approved for 1.00 contact hour(s) which includes 1.00 hour(s) of pharmacology. Activity ID # 21855

This activity was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support

Disclosure of Unlabeled Use

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact AKH at tbrignoni@akhcme.com.

Privacy Policy

AKH Inc. Privacy Policy

When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:

  • We work with several accredited companies who are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a joint-provider, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years.
  • Commercial supporters of CME/CE activities on our Web site will receive only aggregated data about CME/CE activities that are relevant to their interests and/or the courses they support.
  • Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities.

We may use the information we collect as otherwise permitted in this Privacy Policy.


myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue